To explore ICG-001’s impact on metabolic changes associated with glioma differentiation after disrupting the CBP/β-Catenin interaction, we treated patient-derived GBM cell lines PBT147 and PBT030 with ICG-001 (0, 5, or 10 μM) for 24 and 72 h (Figure 3). This evidence concerns the gene CREBBP and central nervous system cancer.